Skip to main content
Signal8

Accustem Sciences Inc. (ACUT)

AccuStem Sciences, Inc. operates as a life science firm committed to improving the outlook for individuals battling cancer. Its primary innovation is the StemPrintER technology, an advanced multi-gene prognostic assay designed to predict the likelihood of recurrence for patients with Endocrine receptor-positive /HER2- breast cancer. The company also offers Spare, a related diagnostic tool that expands upon StemPrintER by incorporating two additional clinical markers. AccuStem Sciences, Inc. is based in New York, New York.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Accustem Sciences Inc. logo

Accustem Sciences Inc.

OTC:ACUTHealthcare
-9.23%$0.1180
Mkt Cap$1.9M
EV-
Float8.49M
O/S16.07M
VOL610 sh
$ Vol$74
RVOL0.22×
Inst Own-
SI<0.1%
Net Cash/Sh-
Dilution
Accustem Sciences Inc. logoOTC:ACUT$0.1180-9.23%
FormDescription
NT 10-Q
SEC Filing
10-Q
10-Q
10-K
Annual Report
NT 10-K
SEC Filing
8-K
8.01
10-Q
Quarterly Report
10-Q
Quarterly Report
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
10-Q
Quarterly Report
NT 10-Q
SEC Filing
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
10-K
Annual Report
NT 10-K
SEC Filing
SEC STAFF ACTION
SEC Filing
4
Statement of Changes in Beneficial Ownership
8-K/A
4.01
8-K
4.01
10-Q
Quarterly Report
NT 10-Q
SEC Filing
10-Q
Quarterly Report
NT 10-Q
SEC Filing
10-Q
Quarterly Report

1-25 of 77

    Accustem Sciences Inc. (ACUT) SEC Filings: 10-K, 10-Q, 8-K | Signal8